ArticlePloS one2018
Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Drinking Water Chlorination Impact on Fecal Carriage of Extended-Spectrum Beta-Lactamase-ProducingEnvironmental health perspectives · 2022Trial
- Population Ecology-Quantitative Microbial Risk Assessment (QMRA) Model for Antibiotic-Resistant and SusceptibleEnvironmental science & technology · 2025Article
- Residence-colonization trade-off and niche differentiation enable coexistence of Escherichia coli phylogroups in healthy humans.The ISME journal · 2025Article
- Human carriage of ESBL/pAmpC-producingMicrobiology spectrum · 2024Article
- Recovery of the gut microbiome following enteric infection and persistence of antimicrobial resistance genes in specific microbial hosts.Scientific reports · 2023Article
- Longitudinal Study of Dynamic Epidemiology of Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Pigs and Humans Living and/or Working on Pig Farms.Microbiology spectrum · 2023Article
- Colonization dynamics of extended-spectrum beta-lactamase-producing Enterobacterales in the gut of Malawian adults.Nature microbiology · 2022Article
- A role for ColV plasmids in the evolution of pathogenic Escherichia coli ST58.Nature communications · 2022Article
- Impact of a Regulation Restricting Critical Antimicrobial Usage on Prevalence of Antimicrobial Resistance inFrontiers in veterinary science · 2022Article
- Clustered Regularly Interspaced Short Palindromic Repeats Genotyping of Multidrug-ResistantFrontiers in microbiology · 2022Article
- Presence of the Extended-Spectrum-β-Lactamase and Plasmid-Mediated AmpC-Encoding Genes inAntibiotics (Basel, Switzerland) · 2021Article
- Human faeces-associated extended-spectrum β-lactamase-producing Escherichia coli discharge into sanitation systems in 2015 and 2030: a global and regional analysis.The Lancet. Planetary health · 2020Article
- Global Evolution of Pathogenic Bacteria With Extensive Use of Fluoroquinolone Agents.Frontiers in microbiology · 2020Article
- Fecal Carriage Rate of Extended-Spectrum Beta-Lactamase-ProducingOpen forum infectious diseases · 2019Article
- Phenotypic and Molecular Epidemiology of ESBL-, AmpC-, and Carbapenemase-ProducingFrontiers in microbiology · 2019Article
- Reviewing Interventions against Enterobacteriaceae in Broiler Processing: Using Old Techniques for Meeting the New Challenges of ESBLBioMed research international · 2018Review
- Correction: Time to acquire and lose carriership of ESBL/pAmpC producing E. coli in humans in the Netherlands.PloS one · 2018Article
- Enriched Shotgun Sequencing to Assess the Effects of Interventions to Reduce Antimicrobial Use in Neonatal Dairy Calves.Journal of veterinary internal medicineArticle
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A subset of the study population from a cross-sectional study of carriership of ESBL/pAmpC-producing E. coli (ESBL-E) in the general population was followed up by five successive samples over an approximate half year period, leading to six samples in 333 persons. Fecal samples were cultured and analyzed for the presence of E. coli types as characterized by MLST, and ESBL/pAmpC genes were analysed by PCR and sequencing. The study included 255 persons who had a negative first sample, to allow observations of acquiring carriership of ESBL-E. Any individual record thus consisted of a series of snapshots of episodes of presence and absence of ESBL-E carriage. A survival model was built to estimate times to acquire or lose carriership, allowing for any combination of ESBL/pAmpC gene and E. coli MLST type. In carriers, the mean time to lose carriership was 1.1 (95% range 0.8-1.6) years. The estimated mean time to acquire carriership was 3.0 (95% range 1.6-6.3) years. Analysis of these times by ESBL/pAmpC gene found substantial variation among resistance genes both in persistence of carriership and in rates of acquiring carriership: blaCTX-M-1, blaCTX-M-14, blaCTX-M-15, blaCTX-M-27 and blaSHV-12 were easily acquired, but blaCTX-M-1 and blaSHV-12 were also easily lost, while blaCTX-M-15, blaCTX-M-27 and blaCMY-2 were more likely to persist. When in addition bacterial host types were included, some combinations appeared more persistent than others (blaCTX-M-1 in ST10 and ST58; blaCTX-M-14, blaCMY-2, and blaSHV-12 in ST69), or were acquired with higher frequency (blaCTX-M-14 in ST38, ST69, and ST131; blaCTX-M-15 and blaCTX-M-27 in ST131; blaSHV-12 in ST69). The relatively short duration of carriership means that when an intervention drastically reduces the exposure of humans to ESBL-E, the prevalence will be halved in 0.66 years. The observed differences between carriage rates of ESBL/pAmpC genes and E. coli strains need further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.